A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
A phase 1/2 trial of Adebrelimab, Cisplatin and SHR-A2102 in oesophageal cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
Overview
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer is a phase 1/2 interventional study registered as NCT06474468 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 148 participants planned, started 2024-06-20 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A2102；Adebrelimab；Cisplatin.
Similar pages
not linked directly; found by shared links- TrialClinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
- TrialA Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
- TrialA Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.